We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Flow Cytometric Immunophenotyping Assessed for Classic Hodgkin Lymphoma

By LabMedica International staff writers
Posted on 24 Mar 2022
Print article
Image: Photomicrograph of classic Hodgkin lymphoma (cHL) fine needle aspiration from a lymph node. The micrograph shows a mixture of cells common in cHL: eosinophils, Reed-Sternberg cells, plasma cells, and histocytes (Photo courtesy of Nephron)
Image: Photomicrograph of classic Hodgkin lymphoma (cHL) fine needle aspiration from a lymph node. The micrograph shows a mixture of cells common in cHL: eosinophils, Reed-Sternberg cells, plasma cells, and histocytes (Photo courtesy of Nephron)

The diagnosis of classic Hodgkin lymphoma (CHL) requires morphologic and immunophenotypic identification of neoplastic Hodgkin and Reed-Sternberg cells (collectively referred to as HRS cells) intermixed with a background of reactive lymphocytes, histiocytes, plasma cells, and eosinophils.

Flow cytometry (FC) studies have been used extensively as part of the workup of most lymphoproliferative disorders, including B- and T-cell lymphomas. The relatively rapid analytic time and minimal requirements for diagnostic samples make FC an attractive initial diagnostic modality, especially when combined with cytology specimens that often have scant cellularity.

A team of Hematologists at the Memorial Sloan Kettering Cancer Center (New York, NY, USA) assessed the testing efficacy of FC performed on small biopsy and cytology specimens for the diagnosis of CHL. They reviewed 131 patients with CHL and 459 patients without CHL during a 3-year period that underwent a small biopsy procedure, including core biopsy and/or cytology evaluation, with concurrent routine clinical FC testing for CHL, assessing performance of FC in small specimens.

Needle aspirates and biopsy needle rinses were filtered and suspended in RPMI. Following resuspension, cells were stained with a 9-antibody panel designed to assess for HRS cells, consisting of fluorescent tagged antibodies. Following staining and incubation, cells were lysed, fixed, washed, and resuspended. Up to 500,000 cells were acquired on a fluorescence-activated cell sorting Canto 10-color flow cytometer (BD Biosciences, San Jose, CA, USA).

The scientists reported that among the 87 confirmed CHL small biopsy specimens considered diagnostic, FC was deemed to be positive in 83, leading to a sensitivity of 95.4%. For an analysis of the 24 fine needle aspiration (FNA) specimens with confirmed CHL, FC was positive in 22, resulting in a sensitivity of 91.67%. Among the negative control specimens, 390 small biopsy–derived specimens were considered to be negative by FC, thus leading to a specificity of 98.2%; 185 FNA-derived specimens were considered negative by FC, resulting in a specificity of 99.46%.

The authors concluded that although FC diagnosis of CHL was historically considered unfeasible, their findings in a real-world clinical setting suggest that FC adds diagnostic value to small biopsy evaluation, reducing time to treatment, costs, and invasive excisional procedures. The study was published in the April, 2022 issue of the journal Archives of Pathology and Laboratory Medicine.

Related Links:
Memorial Sloan Kettering Cancer Center
BD Biosciences 

Gold Supplier
Clinical Chemistry Reagents
SEKURE Clinical Chemistry Reagents
New
Molecular Diagnostic System
FlashDetect Flash48
New
Silver Supplier
Receptor Destroying Enzyme
RDE II (Receptor Destroying Enzyme)
New
High-Throughput Nucleic Acid Extractor
Stream SP96

Print article

Channels

Clinical Chem.

view channel
Image: The analysis pipeline used to investigate associations between blood metabolites, later life brain imaging measures, and genetic risk for Alzheimer’s disease (Photo courtesy of University College London)

Lipid Measurements Show Potential as Alzheimer’s Disease Biomarkers

Brain changes accompanying ageing are varied and can include pathologies that lead to cognitive impairment, the commonest of which is Alzheimer’s disease (AD). Identifying blood-based signatures of brain... Read more

Molecular Diagnostics

view channel
Image: This image depicts a DNA molecule that is methylated on both strands on the center cytosine. DNA methylation plays an important role for epigenetic gene regulation in development and cancer (Photo courtesy of Wikimedia Commons)

Study Supports Use of Methylated DNA Biomarkers for Cancer Diagnosis and Prognosis

A recent study added weight to the theory that methylated DNA biomarkers could be used for cancer diagnosis and prognosis. Methylation is a biological process by which methyl groups are added to a DNA molecule.... Read more

Industry

view channel
Image: QIAGEN has acquired a majority stake in enzymes provider BLIRT S.A. (Photo courtesy of QIAGEN)

Qiagen Acquires Enzymes Provider Blirt to Strengthen Sample Technologies Business

QIAGEN N.V. (Venlo, Netherlands) has signed agreements to acquire a 96% majority ownership stake in BLIRT S.A. (Gdansk, Poland), a manufacturer of recombinant enzymes for the life science industry.... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.